PT1373256E - Antagonistas dos ccr5 uteis para tratamento de sida - Google Patents

Antagonistas dos ccr5 uteis para tratamento de sida

Info

Publication number
PT1373256E
PT1373256E PT02725381T PT02725381T PT1373256E PT 1373256 E PT1373256 E PT 1373256E PT 02725381 T PT02725381 T PT 02725381T PT 02725381 T PT02725381 T PT 02725381T PT 1373256 E PT1373256 E PT 1373256E
Authority
PT
Portugal
Prior art keywords
ccr5
utah
antagonists
aids treatment
aids
Prior art date
Application number
PT02725381T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of PT1373256E publication Critical patent/PT1373256E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/18Sulfonamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
PT02725381T 2001-03-29 2002-03-27 Antagonistas dos ccr5 uteis para tratamento de sida PT1373256E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27993801P 2001-03-29 2001-03-29

Publications (1)

Publication Number Publication Date
PT1373256E true PT1373256E (pt) 2005-11-30

Family

ID=23070981

Family Applications (1)

Application Number Title Priority Date Filing Date
PT02725381T PT1373256E (pt) 2001-03-29 2002-03-27 Antagonistas dos ccr5 uteis para tratamento de sida

Country Status (29)

Country Link
US (5) US6720325B2 (https=)
EP (2) EP1373256B1 (https=)
JP (2) JP4248251B2 (https=)
KR (1) KR100613528B1 (https=)
CN (1) CN100519554C (https=)
AR (1) AR033452A1 (https=)
AT (2) ATE299139T1 (https=)
AU (1) AU2002255947B8 (https=)
BR (1) BR0208398A (https=)
CA (1) CA2442227C (https=)
CZ (1) CZ20032636A3 (https=)
DE (2) DE60204951T2 (https=)
DK (1) DK1373256T3 (https=)
ES (2) ES2242856T3 (https=)
HU (1) HUP0400349A3 (https=)
IL (1) IL157551A0 (https=)
MX (1) MXPA03008853A (https=)
MY (1) MY128609A (https=)
NO (1) NO326349B1 (https=)
NZ (1) NZ527768A (https=)
PE (1) PE20020996A1 (https=)
PL (1) PL364560A1 (https=)
PT (1) PT1373256E (https=)
RU (1) RU2316553C2 (https=)
SI (1) SI1373256T1 (https=)
SK (1) SK287521B6 (https=)
TW (1) TWI237638B (https=)
WO (1) WO2002079194A1 (https=)
ZA (1) ZA200307474B (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR033452A1 (es) * 2001-03-29 2003-12-17 Schering Corp Antagonistas de ccr5 utiles para el tratamiento del sida
ATE319703T1 (de) 2001-07-02 2006-03-15 Piperidinverbindungen, die sich als modulatoren der chemokinrezeptoraktivität eignen
SE0200843D0 (sv) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
SE0200844D0 (sv) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
TW200504033A (en) 2002-10-23 2005-02-01 Procter & Gamble Melanocortin receptor ligands
AU2003300911A1 (en) * 2002-12-13 2004-07-09 Smithkline Beecham Corporation Heterocyclic compounds as ccr5 antagonists
PE20040769A1 (es) * 2002-12-18 2004-11-06 Schering Corp Derivados de piperidina utiles como antagonisas ccr5
SE0300957D0 (sv) 2003-04-01 2003-04-01 Astrazeneca Ab Chemical compounds
KR20060100409A (ko) * 2003-11-03 2006-09-20 쉐링 코포레이션 케모킨 수용체 억제제로서 유용한 비피페리디닐 유도체
CA2554465A1 (en) * 2004-02-05 2005-08-25 Schering Corporation Piperidine derivatives useful as ccr3 antagonists
SE0400925D0 (sv) * 2004-04-06 2004-04-06 Astrazeneca Ab Chemical compounds
EA015517B1 (ru) * 2004-04-13 2011-08-30 Инсайт Корпорейшн Производные пиперазинилпиперидина в качестве антагонистов хемокинового рецептора
US8143404B2 (en) * 2004-09-13 2012-03-27 Ono Pharmaceutical Co., Ltd Nitrogenous heterocylic derivative and medicine containing the same as an active ingredient
WO2006071958A1 (en) 2004-12-29 2006-07-06 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
WO2006071875A1 (en) * 2004-12-29 2006-07-06 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
SG158861A1 (en) * 2005-01-06 2010-02-26 Schering Corp Synthesis of ccr5 receptor antagonists
JP2008526862A (ja) * 2005-01-06 2008-07-24 シェーリング コーポレイション ピペラジン化合物の薬学的な塩の調製
JP4822367B2 (ja) * 2005-02-23 2011-11-24 シェーリング コーポレイション ケモカイン受容体のインヒビターとして有用なピペリジニルピペリジン誘導体
EP1858887A1 (en) * 2005-02-23 2007-11-28 Schering Corporation Piperidinyl piperazine derivatives useful as inhibitors of chemokine receptors
JP2009501793A (ja) 2005-07-21 2009-01-22 アストラゼネカ・アクチエボラーグ 新規ピペリジン誘導体
US7462485B2 (en) * 2005-10-07 2008-12-09 Glaser Lawrence F Modified erythrocytes and uses thereof
TW200745087A (en) * 2006-02-24 2007-12-16 Schering Corp CCR5 antagonists useful for treating HIV
WO2008030853A2 (en) * 2006-09-06 2008-03-13 Incyte Corporation Combination therapy for human immunodeficiency virus infection
CA2673233A1 (en) * 2006-12-22 2008-07-03 Schering Corporation Process for preparing ccr-5 receptor antagonists utilizing 4-substituted 1-cyclopropane-sulfonyl-piperidinyl compounds
CA2716838C (en) * 2008-02-29 2014-01-07 Schering Corporation Ccr5 antagonists as prophylactics for preventing hiv infection and methods of inhibiting transmission of same
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5368854A (en) 1992-08-20 1994-11-29 Schering Corporation Use of IL-10 to treat inflammatory bowel disease
WO1994018192A1 (en) 1993-02-12 1994-08-18 Merck & Co., Inc. Piperazine derivatives as hiv protease inhibitors
IL117149A0 (en) 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
US5889006A (en) 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
EP1103276B1 (en) 1995-06-07 2003-09-10 Kimberly-Clark Worldwide, Inc. Inhibition of exoprotein in absorbent article
NZ321575A (en) 1995-10-30 1999-05-28 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4- substituted piperazine derivatives
TW531537B (en) 1995-12-27 2003-05-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives
US5952349A (en) 1996-07-10 1999-09-14 Schering Corporation Muscarinic antagonists for treating memory loss
US5977138A (en) 1996-08-15 1999-11-02 Schering Corporation Ether muscarinic antagonists
CA2296314A1 (en) 1997-07-25 1999-02-04 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
US6066636A (en) 1998-06-30 2000-05-23 Schering Corporation Muscarinic antagonists
EP1013276A1 (en) * 1998-12-23 2000-06-28 Pfizer Inc. Aminoazacycloalkanes as CCR5 modulators
KR100439357B1 (ko) * 1999-05-04 2004-07-07 쉐링 코포레이션 Ccr5 길항제로서 유용한 피페리딘 유도체
SK287418B6 (sk) 1999-05-04 2010-09-07 Schering Corporation Farmaceutický prípravok s obsahom CCR5 antagonistov a súprava s obsahom tohto prípravku
AR033452A1 (es) * 2001-03-29 2003-12-17 Schering Corp Antagonistas de ccr5 utiles para el tratamiento del sida

Also Published As

Publication number Publication date
NZ527768A (en) 2005-03-24
US7008946B2 (en) 2006-03-07
KR20030083014A (ko) 2003-10-23
RU2316553C2 (ru) 2008-02-10
US6900211B2 (en) 2005-05-31
AR033452A1 (es) 2003-12-17
KR100613528B1 (ko) 2006-08-16
SI1373256T1 (sl) 2005-12-31
EP1591444A1 (en) 2005-11-02
CA2442227A1 (en) 2002-10-10
NO20034311L (no) 2003-11-26
US7060701B2 (en) 2006-06-13
US20030008877A1 (en) 2003-01-09
NO20034311D0 (no) 2003-09-26
JP4248251B2 (ja) 2009-04-02
AU2002255947B2 (en) 2005-10-27
CN1547580A (zh) 2004-11-17
HK1083505A1 (en) 2006-07-07
WO2002079194A1 (en) 2002-10-10
EP1373256A1 (en) 2004-01-02
DE60204951T2 (de) 2006-05-11
EP1591444B1 (en) 2010-04-28
CZ20032636A3 (cs) 2003-12-17
ES2342942T3 (es) 2010-07-19
IL157551A0 (en) 2004-03-28
MXPA03008853A (es) 2003-12-04
DE60236218D1 (de) 2010-06-10
CA2442227C (en) 2008-10-28
PE20020996A1 (es) 2002-11-01
US6720325B2 (en) 2004-04-13
SK11962003A3 (sk) 2004-03-02
US20050143390A1 (en) 2005-06-30
MY128609A (en) 2007-02-28
DK1373256T3 (da) 2005-10-10
HK1057363A1 (en) 2004-04-02
US20040157854A1 (en) 2004-08-12
NO326349B1 (no) 2008-11-17
JP2008074862A (ja) 2008-04-03
EP1373256B1 (en) 2005-07-06
US20060063771A1 (en) 2006-03-23
PL364560A1 (en) 2004-12-13
US7098213B2 (en) 2006-08-29
ATE466009T1 (de) 2010-05-15
ES2242856T3 (es) 2005-11-16
SK287521B6 (sk) 2010-12-07
RU2003131879A (ru) 2005-05-10
AU2002255947B8 (en) 2005-11-17
BR0208398A (pt) 2004-06-15
JP2004525157A (ja) 2004-08-19
HUP0400349A3 (en) 2010-03-29
DE60204951D1 (de) 2005-08-11
TWI237638B (en) 2005-08-11
ATE299139T1 (de) 2005-07-15
US20050059666A1 (en) 2005-03-17
ZA200307474B (en) 2004-12-24
CN100519554C (zh) 2009-07-29
HUP0400349A2 (hu) 2004-12-28

Similar Documents

Publication Publication Date Title
PT1373256E (pt) Antagonistas dos ccr5 uteis para tratamento de sida
DE60217715D1 (de) Vorrichtung zur ablation von gewebe
EP1198271A4 (en) DEVICES AND METHODS FOR STIMULATING VAGUE NERVE
DE60214060D1 (de) Vorrichtung zur Bereitstellung von Wegbeschreibung
NO20035156D0 (no) Fremgangsmåter for brönnbehandling
DE60204286D1 (de) Implantierbare vorrichtung
DE60200527D1 (de) Abnehmbare Mittelkonsole
DE60136477D1 (de) Retinoide zur behandlung von emphysem
IL157328A0 (en) Treatment involving dkk-1 or antagonists thereof
DE60218571D1 (de) Einrichtung zur Reinigung von medizinischen Geräten
DE60227963D1 (de) Behandlungssystem
DE50202623D1 (de) Vorrichtung zur entgegennahme von banknoten
DE60137193D1 (de) Betrugssichere Vorrichtung
DE60207811D1 (de) Zusammensetzungen zur entfernung von menschlichem cerumen
ATE250611T1 (de) Pyranoindole zur glaukombehandlung
IT1308959B1 (it) Dispositivo di autotrasfusione post-operatoria particolarmente incardiochirurgia
DE50206226D1 (de) Vorrichtung zum stapelförmigen ablegen von blättern
ATE345818T1 (de) S-methyl-dihydro-ziprasidone zur behandlung von psychiatrischen störungen.
ATA9252000A (de) Vorrichtung zur verkleinerung der überdimensionierten fraktion von spänen
ES1050240Y (es) Conjunto de electrodos para aparatos de electroterapia.
FI20010458A0 (fi) Häkki
ES1050974Y (es) Cenicero desechable.
NO20013207D0 (no) Behandlingsbenk
ES1049899Y (es) Cenicero perfeccionado.
AT3949U3 (de) Vorrichtung zur körperlichen ertüchtigung von personen